Synergistic cytotoxicity of acidity and 3,4-dideoxyglucosone-3-ene under the existence of lactate in peritoneal dialysis fluid

Therapeutic Apheresis and Dialysis

Volumn 9, Issue 2, 2005, Pages 182-187

  Tomo, Tadashi ^a   Okabe, Eiji ^a   Yamamoto, Takashi ^b   Namoto, Shinji ^b   Iwashita, Tomohiko ^a   Matsuyama, Kazuhiro ^a   Kadota, Jyunichi ^a   Nasu, Masaru ^a  

^a OITA UNIVERSITY   (Japan)

^b JMS Co Ltd   (Japan)

Author keywords

3,4 Dideoxyglucosone 3 ene(3,4 DGE); Human peritoneal mesothelial cells; Lactate; Peritoneal dialysis fluid; Synergistic cytotoxicity

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 3,4 DIDEOXYGLUCOSON 3 ENE; DEOXYGLUCOSE; LACTIC ACID; PERITONEAL DIALYSIS FLUID; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG;

ACIDITY; CELL VIABILITY; CONFERENCE PAPER; CYTOTOXICITY; HUMAN; HUMAN CELL; MESOTHELIUM CELL; PERITONEAL DIALYSIS; PERITONEUM; PH; PRIORITY JOURNAL;

CELL SURVIVAL; CELLS, CULTURED; DIALYSIS SOLUTIONS; DRUG SYNERGISM; EPITHELIAL CELLS; GLUCOSE; HUMANS; HYDROGEN-ION CONCENTRATION; LACTIC ACID; PERITONEAL DIALYSIS; PERITONEUM; PYRONES; TIME FACTORS;

EID: 19544394066     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1774-9987.2005.00228.x     Document Type: Conference Paper

References (25)

1. Witowski J, Korybalska K, Wisniewska J et al. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 2000;11:729-39.
2. Di Paolo N, Garosi G, Traversari L, Di Paolo M. Mesothelial biocompatibility of peritoneal dialysis solutions. Perit Dial Int 1993;13 (Suppl 2): S109-12.
3. Breborowicz A, Rodela H, Karon J, Martis L, Oreopoulos DG. In vitro simulation of the effect of peritoneal dialysis solution on mesothelial cells. Am J Kidney Dis 1997;29:404-9.
4. Witowski J, Wisniewska J, Korybalska K et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001;12:2434-41.
5. Lage C, Pischetsrieder M, Aufricbt C, Jorres A, Schilling H, Passlick-Deetjen J. First in vitro and in vivo experiences with Stay-Safe Balance, a pH-neutral solution in a dual-chambered bag. Perit Dial Int 2000;20 (Suppl 5): S28-32.
6. Topley N, Kaur D, Petersen MM et al. Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: Influence on mesothelial cell and neutrophil function. Kidney Int 1996;49: 1447-56.
7. Witowski J, Topley N, Jorres A, Liberek T, Coles GA, Williams JD. Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 1995;47:282-93.
8. De Vriese AS, Mortier S, Lameire NH. What happens to the peritoneal membrane in long-term peritoneal dialysis? Perit Dial Int 2001;21 (Suppl. 3): S9-18.
9. Wieczorowska-Tobis K, Polubinska A, Schaub TP et al. Influence of neutral-pH dialysis solutions on the peritoneal membrane: A long-term investigation in rats. Perit Dial Int 2001;21 (Suppl. 3): S108-13.
10. Moriishi M, Kawanishi H, Kawai T et al. Influence of pH-neutral peritoneal dialysis solution. Adv Perit Dial 2002;18:68-71.
11. Musi B, Carlsson O, Rippe A, Wieslander A, Rippe B. Effects of acidity, glucose degradation products, and dialysis fluid buffer choice on peritoneal solute and fluid transport in rats. Perit Dial Int 1998;18:303-10.
12. Welten AG, Schalkwijk CG, ter Wee PM, Meijer S, van den Bom J, Beelen RJ. Single exposure of mesothelial cells to glucose degradation products (GDPs) yields early advanced glycation end-products (AGEs) and a proinflammatory response. Peril Dial Int 2003;23:213-21.
13. Linden T, Cohen A, Deppisch R, Kjellstrand P, Wieslander A. 3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int 2002;62:697-703.
14. Zareie M, Hekking LH, Welten AG et al. van den Born Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo. Nephrol Dial Transplant 2003;18:2629-37.
15. Fuminori K, Sadanori M, Yoshiyuki A et al. Immunosuppressive effects of 3 4-Dideoxyglucosone-3-ene an intermediate in the Maillard Reaction. J Agric Food Chem 1994;42: 2068-73.
16. Anet EFLJ. Degradation of carbohydrates III. Unsaturated hexosones. Ausl J Chem 1962;15:503-9.
17. Stylianou E, Jenner LA, Davies M, Coles GA, Williams JD. Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int 1990;37:1563-70.
18. Chung-Welch N, Patton WF, Shepro D, Cambria RP. Two-stage isolation procedure for obtaining homogenous populations of microvascular endothelial and mesothelial cells from human omentum. Microvasc Res 1997;54:121-34.
19. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res 1987;47:936-42.
20. Horiuchi T, Miyamoto K, Miyamoto S et al. Image analysis of remesothelialization following chemical wounding of cultured human peritoneal mesothelial cells: The role of hyaluronan synthesis. Kidney Int 2003;64:2280-90.
21. Morgan LW, Wieslander A, Davies M et al. Glucose degradation products (GDP) retard remesothelialization independently of D-glucose concentration. Kidney Int 2003;64:1854-66.
22. Liberek T, Topley N, Jorres A et al. Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron 1993;65:260-5.
23. Niels Borregaard and TroelsHerlin. Energy metabolism of human neutrophils during phagocytosis. J Clin Invest 1982;70:550-7.
24. Schambye HT. Effect of different buffers on the biocompatibility of CAPD solutions. Perit Dial Int 1996;16 (Suppl. 1): S130-6.
25. Wieslander A, Linden T, Kjellstrand P. Glucose degradation products in peritoneal dialysis fluids: How they can be avoided. Perit Dial Int 2001;21 (Suppl. 3): S119-24.